Moderna, Merck melanoma vaccine succeeds in Phase 3; shares surge up to 83%
MRNA Moderna Inc
$62.96 -2.33%
View chart & analysis → 
- 1Moderna's shares jumped as much as 83% in pre-market trading on news of late-stage clinical success for its personalized melanoma vaccine developed with Merck
- 2The combination of intismeran autogene and Keytruda improved recurrence-free survival versus Keytruda alone and also reduced the risk of metastasis
- 3This marks the first Phase 3 positive result for a personalized cancer vaccine; exact figures have not been disclosed, and the earliest potential approval would come in 2027
This 3-line summary is compiled from the report below.
Barrons.com +7 View original ↗
오늘의 AI 픽 5종목, 무료로 전부 공개합니다숨기는 것 없이 — 지난 픽의 성적표(S&P500 대비)까지 그대로 보여드립니다